{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:43:23Z","timestamp":1793256203638,"version":"4.5.0"},"reference-count":36,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)\u2013targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received \u22651 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses \u22650.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer.<\/jats:p>\n                    <jats:p>See related commentary by Hage Chehade et al., p. 20.<\/jats:p>\n                    <jats:p>See related article by Nolan-Stevaux et al., p. 90.<\/jats:p>\n                    <jats:p>This article is featured in Selected Articles from This Issue, p. 5<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-23-0964","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T10:19:19Z","timestamp":1697797159000},"page":"76-89","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study"],"prefix":"10.1158","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-672X","authenticated-orcid":false,"given":"William K.","family":"Kelly","sequence":"first","affiliation":[{"name":"1Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania."},{"name":"2Sarah Cannon Research Institute, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-0741","authenticated-orcid":false,"given":"Daniel C.","family":"Danila","sequence":"additional","affiliation":[{"name":"3Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"4Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5789","authenticated-orcid":false,"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"5National Taiwan University Hospital, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9420-7162","authenticated-orcid":false,"given":"Jae-Lyun","family":"Lee","sequence":"additional","affiliation":[{"name":"6Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"7National Cancer Center Hospital East, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-4840","authenticated-orcid":false,"given":"Patrick J.","family":"Ward","sequence":"additional","affiliation":[{"name":"2Sarah Cannon Research Institute, Nashville, Tennessee."},{"name":"8Oncology Hematology Care, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"9Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-3022","authenticated-orcid":false,"given":"David","family":"Pook","sequence":"additional","affiliation":[{"name":"10Monash Health, Clayton, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-4199","authenticated-orcid":false,"given":"Miso","family":"Kim","sequence":"additional","affiliation":[{"name":"11Seoul National University Hospital, Seoul, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya B.","family":"Dorff","sequence":"additional","affiliation":[{"name":"12City of Hope, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-3640","authenticated-orcid":false,"given":"Stefanie","family":"Fischer","sequence":"additional","affiliation":[{"name":"13Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-5348","authenticated-orcid":false,"given":"Yung-Chang","family":"Lin","sequence":"additional","affiliation":[{"name":"14Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-9223","authenticated-orcid":false,"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[{"name":"15Chris O'Brien Lifehouse, University of Sydney, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9288-2236","authenticated-orcid":false,"given":"Christopher","family":"Sumey","sequence":"additional","affiliation":[{"name":"16Sanford Cancer Center, Sioux Falls, South Dakota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-1052","authenticated-orcid":false,"given":"Zhao","family":"Yang","sequence":"additional","affiliation":[{"name":"17Amgen Inc., Thousand Oaks, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8003-1269","authenticated-orcid":false,"given":"Gabor","family":"Jurida","sequence":"additional","affiliation":[{"name":"17Amgen Inc., Thousand Oaks, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0960-0937","authenticated-orcid":false,"given":"Kristen M.","family":"Smith","sequence":"additional","affiliation":[{"name":"18Amgen Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-7357","authenticated-orcid":false,"given":"Jamie N.","family":"Connarn","sequence":"additional","affiliation":[{"name":"18Amgen Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3212-0275","authenticated-orcid":false,"given":"Hweixian L.","family":"Penny","sequence":"additional","affiliation":[{"name":"17Amgen Inc., Thousand Oaks, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7035-5855","authenticated-orcid":false,"given":"Julia","family":"Stieglmaier","sequence":"additional","affiliation":[{"name":"19Amgen Research (Munich) GmbH, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-7388","authenticated-orcid":false,"given":"Leonard J.","family":"Appleman","sequence":"additional","affiliation":[{"name":"20UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"2024011208163688400_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2024011208163688400_bib2","article-title":"Cancer Fact Sheets, Prostate"},{"key":"2024011208163688400_bib3","doi-asserted-by":"crossref","first-page":"64447","DOI":"10.18632\/oncotarget.10901","article-title":"Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer","volume":"7","author":"Wadosky","year":"2016","journal-title":"Oncotarget"},{"key":"2024011208163688400_bib4a","unstructured":"Cancer Stat Facts: Prostate Cancer; [about 4 screens]. [cited 2023 Jul 3]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"2024011208163688400_bib4","first-page":"339","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep Urol"},{"key":"2024011208163688400_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"2024011208163688400_bib6","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/cancers15112885","article-title":"Molecular targeted therapies in metastatic prostate cancer: recent advances and future challenges","volume":"15","author":"Sorrentino","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2024011208163688400_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-020-00978-z","article-title":"Novel therapies are changing treatment paradigms in metastatic prostate cancer","volume":"13","author":"Powers","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2024011208163688400_bib8","article-title":"Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789. 2023 Feb 28 [cited 2023 Jul 20]"},{"key":"2024011208163688400_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"2024011208163688400_bib10","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024011208163688400_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"key":"2024011208163688400_bib12","doi-asserted-by":"crossref","first-page":"901365","DOI":"10.3389\/fimmu.2022.901365","article-title":"Novel immune-based treatments for diffuse large B-cell lymphoma: the post-CAR T cell era","volume":"13","author":"Atallah-Yunes","year":"2022","journal-title":"Front Immunol"},{"key":"2024011208163688400_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"2024011208163688400_bib14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2024011208163688400_bib15","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/ajh.26628","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma","volume":"98","author":"Ravi","year":"2023","journal-title":"Am J Hematol"},{"key":"2024011208163688400_bib16","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1002\/cam4.2375","article-title":"Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer","volume":"8","author":"Tucker","year":"2019","journal-title":"Cancer Med"},{"key":"2024011208163688400_bib17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2024011208163688400_bib18","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1200\/JCO.2021.39.15_suppl.5013","article-title":"Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"De Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024011208163688400_bib19","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.869","article-title":"Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE\u00ae) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"31 Suppl 4","author":"Tran","year":"2020","journal-title":"Ann Oncol"},{"key":"2024011208163688400_bib20","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.3390\/cancers14164034","article-title":"STEAP1\u20134 (six-transmembrane epithelial antigen of the prostate 1\u20134) and their clinical implications for prostate cancer","volume":"14","author":"Xu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024011208163688400_bib21","doi-asserted-by":"crossref","article-title":"AMG 509: a novel, humanized, half-life extended, bispecific STEAP1 \u00d7 CD3 T cell recruiting XmAb\u00ae 2+1 antibody","author":"Nolan-Stevaux","DOI":"10.1158\/1538-7445.AM2020-DDT02-03"},{"key":"2024011208163688400_bib22","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.19.00646","article-title":"Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in meta\u00adstatic castration-resistant prostate cancer","volume":"37","author":"Danila","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024011208163688400_bib23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat Commun"},{"key":"2024011208163688400_bib24","article-title":"Boost and attack approach for metastatic prostate cancer therapy! Fred Hutch Cancer Center","author":"Lee Lab, Human Biology and Clinical Research Divisions, Cancer Consortium"},{"key":"2024011208163688400_bib25","article-title":"AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2+1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer. Cancer Discov 2024;14:90\u2013103","author":"Nolan-Stevaux","year":""},{"key":"2024011208163688400_bib26","doi-asserted-by":"crossref","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"MAbs"},{"key":"2024011208163688400_bib27","article-title":"Project Optimus. Reforming the dose optimization and dose selection paradigm in oncology"},{"key":"2024011208163688400_bib28","author":"The Human Protein Atlas. STEAP1"},{"key":"2024011208163688400_bib29","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2024011208163688400_bib30","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","article-title":"Critical aspects of the Bayesian approach to phase I cancer trials","volume":"27","author":"Neuenschwander","year":"2008","journal-title":"Stat Med"},{"key":"2024011208163688400_bib31","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024011208163688400_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2024011208163688400_bib33","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"2024011208163688400_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest Package: tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J Stat Softw"},{"key":"2024011208163688400_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Methodol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-23-0964\/3373514\/cd-23-0964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/14\/1\/76\/3402272\/76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/14\/1\/76\/3402272\/76.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:22:18Z","timestamp":1730370138000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/14\/1\/76\/732544\/Xaluritamig-a-STEAP1-CD3-XmAb-2-1-Immune-Therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,20]]},"published-print":{"date-parts":[[2024,1,12]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0964","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.24988598.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988598","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988586","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988586.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988595","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988592","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988595.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988592.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988589.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.24988589","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.7022645.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.7022645","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]}}}